Drug intelligence / Profile preview

Cyraflora

Development stage: Unknown
Lead developer: Systopic Laboratories
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Cyraflora is a synbiotic supplemental therapy developed by Systopic Laboratories, a company specializing in gastroenterology. It is formulated as a capsule containing a combination of ten probiotic strains and a prebiotic to help maintain and restore healthy gut flora. The probiotic components include *Bacillus clausii* spores, *Bacillus mesentericus*, *Bifidobacterium lactis*, *Clostridium butyricum*, *Lactobacillus acidophilus*, *Lactobacillus paracasei*, *Lactobacillus rhamnosus*, *Saccharomyces boulardii*, *Streptococcus faecalis*, and *Lactic acid bacillus*. These are complemented by the prebiotic fructo-oligosaccharides (FOS), which support the growth of beneficial bacteria. Cyraflora is primarily used in India for the management of irritable bowel syndrome (IBS), diarrhea, and the maintenance of intestinal health following surgery.

Brand names: Cyraflora

Beyond the preview

Go deeper on Cyraflora.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyraflora.

Explore the full profile